BioPharmSignal logoBioPharmSignal

Biotech News

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SAB Biotherapeutics (SABS)SAB BiotherapeuticsEarnings

Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027 Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in

Open original release

Related news

SABSSAB Biotherapeutics2026-05-29 12:00 EST

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SABSSAB Biotherapeutics2026-04-22 11:00 EST

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

GRIGRI Bio2026-05-14 08:35 EST

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

GPCRStructure Therapeutics2026-05-07 20:06 EST

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

ZURAZura Bio2026-05-07 11:30 EST

Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates

ZURAZura Bio2026-03-19 20:05 EST

Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates

KNSAKiniksa2026-04-28 11:30 EST

Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio Execution

CLDXCelldex Therapeutics2026-05-07 20:01 EST

Celldex Reports First Quarter Financial Results and Provides Corporate Update

KYMRKymera2026-04-30 11:00 EST

Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update

ANABAnaptysBio, Inc.2026-05-12 20:15 EST

Anaptys Announces First Quarter 2026 Financial Results and Provides Business Update

View all latest news

SAB Biotherapeutics

SAB Biotherapeutics is a biopharmaceutical company focused on human polyclonal antibodies and immune therapy. Its platform aims to create broad immune responses for infectious and inflammatory diseases.

Recent company news

SABSSAB Biotherapeutics2026-07-07 12:00 EST

Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes

SABSSAB Biotherapeutics2026-05-29 12:00 EST

SAB BIO to Present Data on SAB-142 at The American Diabetes Association’s 2026 Scientific Sessions and FOCIS 2026 Annual Meeting

SABSSAB Biotherapeutics2026-05-12 11:30 EST

SAB BIO Reports Q1 2026 Financial Results and Recent Business Highlights

SABSSAB Biotherapeutics2026-05-05 12:30 EST

SAB BIO to Host First Quarter 2026 Financial Results Conference Call and Webcast on May 12, 2026, 08:30 AM ET

SABSSAB Biotherapeutics2026-04-22 11:00 EST

SAB BIO Presents Additional Clinical and Mechanistic Data from SAB-142 Phase 1 Trial in Adult Patients with Established Autoimmune Type 1 Diabetes at IDS 2026

Stock data

Close
3.44 USD
Market cap
266.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States